High-Throughput Genotyping of Plasmodium vivax in the Peruvian Amazon via Molecular Inversion Probes

Zachary R. Popkin-Hall,Karamoko Niare,Rebecca Crudale,Alfred Simkin,Abebe A. Fola,Juan F. Sanchez,Danielle L. Pannebaker,David J. Giesbrecht,Isaac E. Kim Jr.,Ozkan Aydemir,Jeffrey A. Bailey,Hugo O. Valdivia,Jonathan J. Juliano
DOI: https://doi.org/10.1101/2024.06.27.24309599
2024-06-28
Abstract:Plasmodium vivax transmission occurs throughout the tropics and is an emerging threat in areas of Plasmodium falciparum decline, causing relapse infections that complicate treatment and control. Targeted sequencing for P. falciparum has been widely deployed to detect population structure and the geographic spread of antimalarial and diagnostic resistance. However, there are fewer such tools for P. vivax. Leveraging global variation data, we designed four molecular inversion probe (MIP) genotyping panels targeting geographically differentiating SNPs, neutral SNPs, putative antimalarial resistance genes, and vaccine candidate genes. We deployed these MIP panels on 866 infections from the Peruvian Amazon and identified transmission networks with clonality (IBD>0.99), copy number variation in Pvdbp and multiple Pvrbps, fixation of putative antimalarial resistance, and balancing selection in 13 vaccine candidate genes. Our MIP panels are the broadest genotyping panel currently available and are poised for successful deployment in other regions of P. vivax transmission.
Infectious Diseases (except HIV/AIDS)
What problem does this paper attempt to address?
This paper mainly discusses the use of Molecular Inversion Probes (MIPs) for high-throughput genotyping of Plasmodium vivax in the Peruvian Amazon region. Currently, genomic studies on Plasmodium falciparum, the causative agent of severe malaria, are more abundant than those on Plasmodium vivax. The researchers designed four MIP genotyping panels targeting geographic differentiation SNPs, neutral SNPs, drug resistance genes, and vaccine candidate genes for the analysis of 866 infection cases. The paper points out that Plasmodium vivax is widely spread worldwide, and its complex biological characteristics, such as liver-stage dormancy and early gametocyte formation, make control and treatment more challenging. Previous studies have mainly focused on Plasmodium falciparum, and there is relatively limited genomic epidemiological research on Plasmodium vivax, particularly in South America. The research team applied these MIP panels in the Peruvian Amazon region, revealing transmission networks, clonality (IBD>0.99), Pvdbp and multiple Pvrbps copy number variations, fixed drug resistance, and balanced selection of 13 vaccine candidate genes. These MIP panels are currently the most comprehensive genotyping tools and are applicable to other regions with Plasmodium vivax transmission. Using this approach, the researchers discovered a range of genetic characteristics, including potential fixed mutations associated with drug resistance, as well as signs of balanced selection in multiple red blood cell invasion protein genes, which may be related to vaccine efficacy. In addition, the study identified highly related (IBD ≥ 0.99) clonal transmission networks across years. In conclusion, this paper aims to fill the gaps in Plasmodium vivax genomic research by developing and applying MIP technology, in order to better understand the biological characteristics and transmission dynamics of this malaria parasite, and provide information for malaria control and elimination strategies.